Clinical Trial Update: Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the safety and reactogenicity of GlaxoSmithKline's DTPa/Hib vaccine administered at 3, 4, and 5 months of age has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Tetanus

Drugs mentioned

• DTPa/Hib Vaccine (diphtheria-tetanus-pertussis acellular and Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED